Ascendis Pharma A (ASND) Loans - Gross (2012 - 2026)
Ascendis Pharma A (ASND) posted Loans - Gross of $1.3 billion for Q1 2026, up 2.19% sequentially from $1.3 billion in Q4 2025, and up 36.09% YoY from $969.3 million in Q1 2025.
Ascendis Pharma A (ASND) Loans - Gross (2012 - 2026) Analysis & Trends
Ascendis Pharma A has reported Loans - Gross for 15 years, with the latest figure at $1.3 billion in Q1 2026.
- Quarterly Loans - Gross rose 36.09% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 36.09% YoY) and the FY2025 annual result came in at $1.3 billion, down 44.44% from the prior year.
- Loans - Gross rose to $1.3 billion in Q1 2026 per ASND's latest filing, from $1.3 billion in the prior quarter.
- Over five years, Loans - Gross peaked at $2.3 billion in Q4 2024 and troughed at $737.9 million in Q2 2023.
- A 5-year average of $1.1 billion and a median of $1.1 billion in 2024 frame the typical range for Loans - Gross.
- The sharpest annual moves came in 2024 and 2025: Loans - Gross surged 193.2% in 2024, then plunged 44.44% in 2025.
- Over 5 years, Loans - Gross stood at $942.2 million in 2022, then decreased by 15.89% to $792.4 million in 2023, then surged by 193.2% to $2.3 billion in 2024, then plunged by 44.44% to $1.3 billion in 2025, then gained by 2.19% to $1.3 billion in 2026.
- According to Business Quant data, Loans - Gross over the past three periods registered $1.3 billion, $1.3 billion, and $1.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Loans - Gross (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | 1.32 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.32 Bn |
| Dec 31, 2025 | 1.29 Bn |
| Sep 30, 2025 | 1.19 Bn |
| Jun 30, 2025 | 1.08 Bn |
| Mar 31, 2025 | 969.30 Mn |
| Dec 31, 2024 | 2.32 Bn |
| Sep 30, 2024 | 1.07 Bn |
| Jun 30, 2024 | 912.92 Mn |
| Mar 31, 2024 | 867.97 Mn |
| Dec 31, 2023 | 792.44 Mn |
| Sep 30, 2023 | 798.90 Mn |
| Jun 30, 2023 | 737.94 Mn |
| Mar 31, 2023 | 869.24 Mn |
| Dec 31, 2022 | 942.17 Mn |
| Sep 30, 2022 | 1.09 Bn |
| Jun 30, 2022 | 1.19 Bn |
| Mar 31, 2022 | 1.26 Bn |
| Dec 31, 2021 | 1.42 Bn |
| Sep 30, 2021 | 1.13 Bn |
| Jun 30, 2021 | 827.92 Mn |